Promising drug cocktail aims to stop breast cancer recurrence
NCT ID NCT05467891
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study is for people with a type of breast cancer (hormone receptor-positive, HER2-negative) that has come back in the same area after initial treatment. The goal is to see if adding the drug ribociclib to standard hormone therapy can help prevent the cancer from returning again. About 200 participants will receive this combination and be followed for up to 6 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown University
RECRUITINGWashington D.C., District of Columbia, 20057, United States
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
-
New York University Clinical Cancer Center
RECRUITINGNew York, New York, 10016, United States
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
Orlando Health Cancer Institute
ACTIVE_NOT_RECRUITINGOrlando, Florida, 32806, United States
-
Parkview Research Center
RECRUITINGFort Wayne, Indiana, 46845, United States
-
Penn State Cancer Institute
RECRUITINGHershey, Pennsylvania, 17033, United States
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213, United States
Contact Email: •••••@•••••
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
-
Tufts Medical Center
RECRUITINGBoston, Massachusetts, 02111, United States
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
-
University of Arizona
RECRUITINGPhoenix, Arizona, 85004, United States
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
-
University of Iowa Hospitals and Clinics
RECRUITINGIowa City, Iowa, 52242, United States
-
University of Michigan Health System
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Michigan Health-West
TERMINATEDWyoming, Michigan, 49519, United States
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
-
University of New Mexico Comprehensive Cancer Center
RECRUITINGAlbuquerque, New Mexico, 87102, United States
-
University of Virginia Health System
RECRUITINGCharlottesville, Virginia, 22908, United States
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Virtual therapy may ease breast cancer treatment side effects
- A gentle jog might be the key to better sleep for breast cancer survivors
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Ovarian suppression plus tamoxifen: a Long-Term bet against breast cancer recurrence
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- New drug cocktail aims to outsmart resistant breast cancer